Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON Monitor

Z. Pavelek, O. Soucek, J. Krejsek, I. Sejkorova, O. Vysata, B. Klimová, F. Angelucci, P. Stourac, M. Valis, M. Peterka, L. Sobisek, M. Novotny

. 2023 ; 2023 (-) : 4653627. [pub] 20230407

Jazyk angličtina Země Egypt

Typ dokumentu pozorovací studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23010467

BACKGROUND: The QuantiFERON®-Monitor (QFM) is an assay that measures interferon-γ production and was developed to provide an objective marker of complex immune response. In this study, we evaluated the use of the QFM test in patients with two forms of multiple sclerosis (MS), relapsing-remitting form treated with fingolimod (fMS) and secondarily progressive form not treated pharmacologically (pMS), and in healthy controls (HC). We hypothesized that IFN-γ levels would be lower in those subjects who are relatively more immunosuppressed and higher in those with normal or activated immune function. METHODS: This single-center observational study was conducted from November 2020 to October 2021 and compared results in three groups of patients: 86 healthy controls, 96 patients with pMS, and 78 fMS. Combination of lyophilized stimulants was added to 1 ml heparinized whole blood within 8 hr of collection. Plasmatic IFN-γ was measured using the ELISA kit for the QFM and data were obtained in IU/ml. RESULTS: The results showed that controls had nearly 2-fold higher levels of IFN-γ (QFM score) in median (q25, q75) 228.00 (112.20, 358.67) than the MS patient groups: pMS 144.80 (31.23, 302.00); fMS 130.50 (39.95, 217.07) which is statistically significant difference P-value: HC vs. pMS = 0.0071; HC vs. fMS = 0.0468. This result was also confirmed by a validation analysis to exclude impact of variable factors, such as disease duration and Expanded Disability Status Scale scores. CONCLUSIONS: Results showed that controls had higher levels of IFN-γ production than the MS patient groups and suggest that MS patients included in this study have a lower ability of immune system activation than HC. Results confirm that fingolimod is able to suppress production of IFN-γ. The fact that the QFM score of MS patients is significantly lower than that of HC may indicate a dysfunctional state of the immune system in baseline conditions.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010467
003      
CZ-PrNML
005      
20230801132438.0
007      
ta
008      
230718s2023 ua f 000 0|eng||
009      
AR
024    7_
$a 10.1155/2023/4653627 $2 doi
035    __
$a (PubMed)37064009
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ua
100    1_
$a Pavelek, Zbysek $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic $1 https://orcid.org/0000000217728781
245    10
$a Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON Monitor / $c Z. Pavelek, O. Soucek, J. Krejsek, I. Sejkorova, O. Vysata, B. Klimová, F. Angelucci, P. Stourac, M. Valis, M. Peterka, L. Sobisek, M. Novotny
520    9_
$a BACKGROUND: The QuantiFERON®-Monitor (QFM) is an assay that measures interferon-γ production and was developed to provide an objective marker of complex immune response. In this study, we evaluated the use of the QFM test in patients with two forms of multiple sclerosis (MS), relapsing-remitting form treated with fingolimod (fMS) and secondarily progressive form not treated pharmacologically (pMS), and in healthy controls (HC). We hypothesized that IFN-γ levels would be lower in those subjects who are relatively more immunosuppressed and higher in those with normal or activated immune function. METHODS: This single-center observational study was conducted from November 2020 to October 2021 and compared results in three groups of patients: 86 healthy controls, 96 patients with pMS, and 78 fMS. Combination of lyophilized stimulants was added to 1 ml heparinized whole blood within 8 hr of collection. Plasmatic IFN-γ was measured using the ELISA kit for the QFM and data were obtained in IU/ml. RESULTS: The results showed that controls had nearly 2-fold higher levels of IFN-γ (QFM score) in median (q25, q75) 228.00 (112.20, 358.67) than the MS patient groups: pMS 144.80 (31.23, 302.00); fMS 130.50 (39.95, 217.07) which is statistically significant difference P-value: HC vs. pMS = 0.0071; HC vs. fMS = 0.0468. This result was also confirmed by a validation analysis to exclude impact of variable factors, such as disease duration and Expanded Disability Status Scale scores. CONCLUSIONS: Results showed that controls had higher levels of IFN-γ production than the MS patient groups and suggest that MS patients included in this study have a lower ability of immune system activation than HC. Results confirm that fingolimod is able to suppress production of IFN-γ. The fact that the QFM score of MS patients is significantly lower than that of HC may indicate a dysfunctional state of the immune system in baseline conditions.
650    _2
$a lidé $7 D006801
650    12
$a roztroušená skleróza $x diagnóza $x farmakoterapie $7 D009103
650    _2
$a fingolimod hydrochlorid $x terapeutické užití $7 D000068876
650    _2
$a interferon gama $7 D007371
650    _2
$a ELISA $7 D004797
650    _2
$a imunitní systém $7 D007107
650    12
$a relabující-remitující roztroušená skleróza $7 D020529
655    _2
$a pozorovací studie $7 D064888
655    _2
$a časopisecké články $7 D016428
700    1_
$a Soucek, Ondrej $u Department of Clinical Immunology and Allergology, University Hospital Hradec Králové, Hradec Králové, Czech Republic
700    1_
$a Krejsek, Jan $u Department of Clinical Immunology and Allergology, University Hospital Hradec Králové, Hradec Králové, Czech Republic $1 https://orcid.org/0000000327786800 $7 nlk19990073429
700    1_
$a Sejkorova, Ilona $u Department of Clinical Immunology and Allergology, University Hospital Hradec Králové, Hradec Králové, Czech Republic
700    1_
$a Vysata, Oldrich $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic
700    1_
$a Klimová, Blanka $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic $1 https://orcid.org/0000000180009766 $7 jo2004259816
700    1_
$a Angelucci, Francesco $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic
700    1_
$a Stourac, Pavel $u Department of Neurology, University Hospital and Masaryk University, Brno, Czech Republic
700    1_
$a Valis, Martin $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic
700    1_
$a Peterka, Marek $u Department of Neurology, Faculty of Medicine and University Hospital Plzen, Charles University in Prague, Plzeň, Czech Republic
700    1_
$a Sobisek, Lukáš $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic $1 https://orcid.org/0000000180712005 $7 xx0238269
700    1_
$a Novotny, Michal $u Department of Neurology, Faculty of Medicine and University Hospital Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic $1 https://orcid.org/0000000315654181
773    0_
$w MED00186351 $t Journal of immunology research $x 2314-7156 $g Roč. 2023, č. - (2023), s. 4653627
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37064009 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132435 $b ABA008
999    __
$a ok $b bmc $g 1963095 $s 1196732
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 2023 $c - $d 4653627 $e 20230407 $i 2314-7156 $m Journal of immunology research $n J. immunol. res. $x MED00186351
LZP    __
$a Pubmed-20230718

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...